Filing scope and business context
The supplied filing is The Female Health Company’s Form 10-K for the fiscal year ended September 30, 2012, with unaudited fourth-quarter results. The filing does not identify VERU Inc. as the registrant; it identifies The Female Health Company (ticker FHCO). Verify the company and filing match the requested issuer.
The company manufactures and sells FC2, a female condom used for contraception and STI/HIV prevention. It operates in one business segment and relies primarily on public-health-sector buyers and large tenders. FC2 was available in 138 countries. Sales are concentrated: UNFPA, John Snow/USAID, and Sekunjalo represented 85% of fiscal 2012 unit sales.
Key financial metrics
| Metric | FY 2012 | FY 2011 |
|---|---|---|
| Net revenue | $35.03 million | $18.57 million |
| Gross profit / margin | $20.62 million / 59% | $9.87 million / 53% |
| Operating income | $10.94 million | $3.30 million |
| Net income | $15.30 million | $5.40 million |
| Diluted earnings per share | $0.53 | $0.19 |
| Cash from operations | $10.36 million | $6.97 million |
| Cash at year-end | $5.29 million | $4.25 million |
| Working capital | $10.97 million | $7.45 million |
| Total assets / stockholders’ equity | $30.45 million / $24.22 million | $19.44 million / $16.75 million |
Fiscal 2012 investing activities used $0.65 million, including $0.72 million of capital expenditures, mainly for Malaysian manufacturing expansion. Financing activities used $8.66 million, primarily for dividends, treasury-share purchases, and tax withholding on cashless option exercises. The company had no revolving borrowings at year-end and reported no required debt-service obligations. Its $2 million revolving credit facility was extended to August 1, 2013.
For Q4 FY 2012, revenue was $9.91 million, gross profit $5.75 million, operating expenses $2.56 million, and net income $8.19 million, or $0.29 per diluted share. The quarter included a $5.08 million income-tax benefit.
Material changes versus the prior year
- Revenue increased 89%; unit sales rose 88%, following delayed Brazil and South Africa orders in FY 2011 and significant orders received in FY 2012, including a 20-million-unit Brazil order.
- Gross margin increased to 59% from 53%, principally because higher volume improved fixed-overhead absorption. Average selling price increased 1%.
- Operating expenses increased to $9.68 million from $6.57 million, primarily due to education and training spending and performance-based incentive compensation.
- Net income growth exceeded operating-income growth in part because the reported income-tax benefit rose to $4.51 million from $2.17 million. Management reduced the valuation allowance against deferred tax assets; the benefit is not equivalent to recurring operating earnings.
- Trade receivables rose to $7.27 million from $2.31 million, reflecting higher sales and order timing. The filing also reports accrued compensation of $2.96 million, versus $0.37 million.
Outlook, risks, and unusual items
- Management said existing cash was expected to fund operations for the next 12 months, while cautioning that adequacy was not assured. No specific revenue or earnings guidance was provided.
- The company planned to invest up to $14 million over six years in education and training, and to offer major purchasers free product equal to 5% of annual purchases beginning in FY 2013. These initiatives may raise expenses or affect gross margin.
- Manufacturing capacity in Malaysia was expanded by 20% to approximately 100 million units annually; the new lines entered production in October 2012. The filing described total FC2 capacity as approximately 100 million units annually.
- Unfilled orders were $11.38 million at November 30, 2012, versus $6.48 million a year earlier; the company expected them to be filled during FY 2013. Orders fluctuate and include later requested delivery dates.
- Key risks include dependence on FC2 as the principal product, concentrated customers, volatile government procurement and tender timing, public-sector funding, foreign-exchange and raw-material costs, competition, regulatory compliance, and reliance primarily on one Malaysian manufacturing facility.
- The company continued quarterly dividends, increasing the rate to $0.06 per share during FY 2012. Future dividends remain at board discretion and are subject to cash-flow and credit-facility conditions.
- The independent auditor issued an unqualified opinion on the financial statements and internal control over financial reporting; management also concluded disclosure controls were effective. No pending legal proceedings were reported.
Important facts for investors to verify
- Confirm issuer identity: the filing text names The Female Health Company, not VERU Inc.
- Assess how much of FY 2012 net income and Q4 earnings reflects the deferred-tax benefit and whether the benefit is repeatable.
- Review customer concentration, order backlog conversion, and the timing and repeatability of large public-sector tenders.
- Verify cash conversion and collection of the year-end receivables increase, alongside accrued compensation and dividend outflows.
- Evaluate the planned education spending, free-product program, manufacturing expansion, and their effects on margins, capacity utilization, and cash.
- Check the subsequent status and terms of the revolving credit facility, dividend policy, and post-year-end production and orders.